Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution
Effective control of musculoskeletal pain (MSP) is one of the main tasks of medical care for the most common rheumatic diseases, such as osteoarthritis (OA) and non-specific back pain (NSBP). Epidemiological surveys have shown that a substantial proportion (about 40–50%) of patients consider their a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2017-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/769 |
| _version_ | 1797876785338122240 |
|---|---|
| author | A. E. Karateev |
| author_facet | A. E. Karateev |
| author_sort | A. E. Karateev |
| collection | DOAJ |
| description | Effective control of musculoskeletal pain (MSP) is one of the main tasks of medical care for the most common rheumatic diseases, such as osteoarthritis (OA) and non-specific back pain (NSBP). Epidemiological surveys have shown that a substantial proportion (about 40–50%) of patients consider their assigned treatment to be ineffective and are dissatisfied with its results. The reasons for this are a phenotypic diversity of MSP, individual responses to analgesic drugs, and comorbidities (particularly metabolic disorders and depression). Placebo-controlled trials have demonstrated that monotherapy with the most popular drugs (non-steroidal anti-inflammatory drugs (NSAIDs), opioids, local glucocorticoid injections, duloxetine, etc.) for the treatment of OA and NSBP provides significant pain relief (>50%) in only nearly one-half of patients. This necessitates comprehensive and individualized patient therapy aimed at different components of the pathogenesis of pain. The first step in the treatment of MSP should be the rational use of NSAIDs. Nimesulide that has a favorable combination of efficacy, good tolerability, and an acceptable cost may be considered as the drug of choice. The important element of treatment for chronic MSP is also the use of slow-acting anti-inflammatory drugs, such as diacerein. |
| first_indexed | 2024-04-10T02:08:03Z |
| format | Article |
| id | doaj.art-f2b3d901ec1c484eb6321a4379907117 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:08:03Z |
| publishDate | 2017-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-f2b3d901ec1c484eb6321a43799071172023-03-13T08:39:25ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2017-09-0111341310.14412/1996-7012-2017-3-4-132042Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solutionA. E. Karateev0ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»Effective control of musculoskeletal pain (MSP) is one of the main tasks of medical care for the most common rheumatic diseases, such as osteoarthritis (OA) and non-specific back pain (NSBP). Epidemiological surveys have shown that a substantial proportion (about 40–50%) of patients consider their assigned treatment to be ineffective and are dissatisfied with its results. The reasons for this are a phenotypic diversity of MSP, individual responses to analgesic drugs, and comorbidities (particularly metabolic disorders and depression). Placebo-controlled trials have demonstrated that monotherapy with the most popular drugs (non-steroidal anti-inflammatory drugs (NSAIDs), opioids, local glucocorticoid injections, duloxetine, etc.) for the treatment of OA and NSBP provides significant pain relief (>50%) in only nearly one-half of patients. This necessitates comprehensive and individualized patient therapy aimed at different components of the pathogenesis of pain. The first step in the treatment of MSP should be the rational use of NSAIDs. Nimesulide that has a favorable combination of efficacy, good tolerability, and an acceptable cost may be considered as the drug of choice. The important element of treatment for chronic MSP is also the use of slow-acting anti-inflammatory drugs, such as diacerein.https://mrj.ima-press.net/mrj/article/view/769скелетно-мышечная больостеоартритнеспецифическая боль в спинеанальгетическая терапиянеудовлетворенность лечениемнестероидные противовоспалительные препаратынимесулиддиацереин |
| spellingShingle | A. E. Karateev Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution Современная ревматология скелетно-мышечная боль остеоартрит неспецифическая боль в спине анальгетическая терапия неудовлетворенность лечением нестероидные противовоспалительные препараты нимесулид диацереин |
| title | Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution |
| title_full | Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution |
| title_fullStr | Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution |
| title_full_unstemmed | Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution |
| title_short | Dissatisfaction with management of musculoskeletal pain: A global problem and methods of its solution |
| title_sort | dissatisfaction with management of musculoskeletal pain a global problem and methods of its solution |
| topic | скелетно-мышечная боль остеоартрит неспецифическая боль в спине анальгетическая терапия неудовлетворенность лечением нестероидные противовоспалительные препараты нимесулид диацереин |
| url | https://mrj.ima-press.net/mrj/article/view/769 |
| work_keys_str_mv | AT aekarateev dissatisfactionwithmanagementofmusculoskeletalpainaglobalproblemandmethodsofitssolution |